Zai Lab Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (11)

Latest Posts

About This Stock More About This Stock
Week In Review: 2018 Results: China Life Science Investment Hits Record Levels
Article By: ChinaBio® Today
Saturday, January 5, 2019 4:28 PM EDT
Investments in China life science set new records in all categories during 2018, reflecting the increasing development of the industry. And these numbers are spectacular even in comparison to an already strong 2017.
In this article: NVCR, ATNX, ZLAB
Read
Week In Review: Two China Biopharmas Raise $1.4 Billion In Hong Kong IPOs
Article By: ChinaBio® Today
Saturday, December 15, 2018 4:06 PM EDT
WuXi AppTec began trading on the Hong Kong Exchange following a $967 million IPO, finishing the first day of trading at the offer price. In May, the company completed a $354 million Shanghai IPO at a price that has now quadrupled after six months.
In this article: ZLAB
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EDT
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Article By: ChinaBio® Today
Saturday, October 27, 2018 5:08 PM EDT
Innovent Biologics has priced its Hong Kong IPO to raise $421 million. The successful IPO shows investors are still interested in young China biopharmas. he IPO values Innovent at $2 billion; its shares will begin trading on October 31.
In this article: CASI, ZLAB
Read
Week In Review: $1.4 Billion In China Life Science Deals And Financings
Article By: ChinaBio® Today
Saturday, September 15, 2018 4:30 PM EDT
Vivo Capital, a US-China healthcare investment firm, closed a new private equity fund at $635 million. The Vivo Opportunity Fund will invest in US and China small to mid-cap public life sciences companies with novel products in development.
In this article: NVCR, ZLAB
Read

PARTNER HEADLINES

Latest Tweets for $ZLAB

No tweets yet!